Selective induction of cancer cell death by targeted granzyme B

Antibodies

Volumn 2, Issue 1, 2013, Pages 130-151

  Oberoi, Pranav ^a   Jabulowsky, Robert A ^a   Wels, Winfried S ^a  

^a INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

Author keywords

Cancer therapy; Epidermal growth factor receptor; ErbB2; Granzyme B; HER2; Recombinant fusion protein; Single chain Fv antibody; Transforming growth factor

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL) PROPYLAMINO] 3 NITROBENZENESULFONYL] BENZAMIDE; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; APOPTOSIS INDUCING FACTOR; CASPASE 3; CHLOROQUINE; DIPEPTIDYL PEPTIDASE I; GLUTATHIONE TRANSFERASE; GRANZYME B; HEAT SHOCK PROTEIN 70; IMMUNOTOXIN; INTERLEUKIN 2; NEUTRALIZING ANTIBODY; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANTIGEN BINDING CELL; ANTIGEN SPECIFICITY; APOPTOSIS; BREAST CARCINOMA; CANCER CELL; CANCER THERAPY; CELL DEATH; CELL VIABILITY; CELLULAR STRESS RESPONSE; CONFOCAL LASER MICROSCOPY; CYTOTOXIC LYMPHOCYTE; CYTOTOXICITY; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; IC 50; IMMOBILIZED METAL AFFINITY CHROMATOGRAPHY; IMMUNITY; IMMUNOGENICITY; KIDNEY CARCINOMA; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW; SQUAMOUS CELL CARCINOMA;

EID: 84885697828     PISSN: 20734468     EISSN: None     Source Type: Journal    
DOI: 10.3390/antib2010130     Document Type: Review

References (102)

1. Maloney, D. G. Immunotherapy for non-Hodgkin's lymphoma: Monoclonal antibodies and vaccines. J. Clin. Oncol. 2005, 23, 6421-6428.
2. Groner, B.; Hartmann, C.; Wels, W. Therapeutic antibodies. Curr. Mol. Med. 2004, 4, 539-547.
3. Hynes, N. E.; Lane, H. A. ERBB receptors and cancer: The complexity of targeted inhibitors. Nat. Rev. Cancer 2005, 5, 341-354.
4. Lan, K. H.; Lu, C. H.; Yu, D. Mechanisms of trastuzumab resistance and their clinical implications. Ann. NY Acad. Sci. 2005, 1059, 70-75.
5. Nahta, R.; Esteva, F. J. HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res. 2006, 8, 215.
6. Weldon, J. E.; Pastan, I. A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer. FEBS J. 2011, 278, 4683-4700.
7. Wels, W.; Biburger, M.; Müller, T.; Dälken, B.; Giesübel, U.; Tonn, T.; Uherek, C. Recombinant immunotoxins and retargeted killer cells: employing engineered antibody fragments for tumorspecific targeting of cytotoxic effectors. Cancer Immunol. Immunother. 2004, 53, 217-226.
8. Pastan, I.; Hassan, R.; Fitzgerald, D. J.; Kreitman, R. J. Immunotoxin therapy of cancer. Nat. Rev. Cancer 2006, 6, 559-565.
9. von Minckwitz, G.; Harder, S.; Hovelmann, S.; Jäger, E.; Al-Batran, S. E.; Loibl, S.; Atmaca, A.; Cimpoiasu, C.; Neumann, A.; Abera, A.; et al. Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas. Breast Cancer Res. 2005, 7, R617-R626.
10. Kreitman, R. J.; Pastan, I. Antibody fusion proteins: Anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin. Cancer Res. 2011, 17, 6398-6405.
11. Kelly, R. J.; Sharon, E.; Pastan, I.; Hassan, R. Mesothelin-targeted agents in clinical trials and in preclinical development. Mol. Cancer Ther. 2012, 11, 517-525.
12. Pai, L. H.; Wittes, R.; Setser, A.; Willingham, M. C.; Pastan, I. Treatment of advanced solid tumors with immunotoxin LMB-1: An antibody linked to Pseudomonas exotoxin. Nat. Med. 1996, 2, 350-353.
13. Azemar, M.; Djahansouzi, S.; Jäger, E.; Solbach, C.; Schmidt, M.; Maurer, A. B.; Mross, K.; Unger, C.; von Minckwitz, G.; Dall, P.; et al. Regression of cutaneous tumor lesions in patients intratumorally injected with a recombinant single-chain antibody-toxin targeted to ErbB2/HER2. Breast Cancer Res. Treat. 2003, 82, 155-164.
14. Keppler-Hafkemeyer, A.; Kreitman, R. J.; Pastan, I. Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies. Int. J. Cancer 2000, 87, 86-94.
15. Schmidt, M.; McWatters, A.; White, R. A.; Groner, B.; Wels, W.; Fan, Z.; Bast, R. C., Jr. Synergistic interaction between an anti-p185HER-2 pseudomonas exotoxin fusion protein [scFv(FRP5)-ETA] and ionizing radiation for inhibiting growth of ovarian cancer cells that overexpress HER-2. Gynecol. Oncol. 2001, 80, 145-155.
16. Weidle, U. H.; Georges, G.; Brinkmann, U. Fully human targeted cytotoxic fusion proteins: New anticancer agents on the horizon. Cancer Genomics Proteomics 2012, 9, 119-133.
17. Gerspach, J.; Wajant, H.; Pfizenmaier, K. Death ligands designed to kill: development and application of targeted cancer therapeutics based on proapoptotic TNF family ligands. Results Probl. Cell Differ. 2009, 49, 241-273.
18. Antignani, A.; Youle, R. J. A chimeric protein induces tumor cell apoptosis by delivering the human Bcl-2 family BH3-only protein Bad. Biochemistry 2005, 44, 4074-4082.
19. Lorberboum-Galski, H. Human toxin-based recombinant immunotoxins/chimeric proteins as a drug delivery system for targeted treatment of human diseases. Expert Opin. Drug Deliv. 2011, 8, 605-621.
20. Hanahan, D.; Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 2011, 144, 646-674.
21. Mahmud, H.; Dälken, B.; Wels, W. S. Induction of programmed cell death in ErbB2/HER2-expressing cancer cells by targeted delivery of apoptosis-inducing factor. Mol. Cancer Ther. 2009, 8, 1526-1535.
22. Liu, Y.; Cheung, L. H.; Thorpe, P.; Rosenblum, M. G. Mechanistic studies of a novel human fusion toxin composed of vascular endothelial growth factor (VEGF)121 and the serine protease granzyme B: Directed apoptotic events in vascular endothelial cells. Mol. Cancer Ther. 2003, 2, 949-959.
23. Dälken, B.; Giesübel, U.; Knauer, S. K.; Wels, W. S. Targeted induction of apoptosis by chimeric granzyme B fusion proteins carrying antibody and growth factor domains for cell recognition. Cell Death Differ. 2006, 13, 576-585.
24. Rosenblum, M. G.; Barth, S. Development of novel, highly cytotoxic fusion constructs containing granzyme B: unique mechanisms and functions. Curr. Pharm. Des. 2009, 15, 2676-2692.
25. Kurschus, F. C.; Jenne, D. E. Delivery and therapeutic potential of human granzyme B. Immunol. Rev. 2010, 235, 159-171.
26. Cullen, S. P.; Brunet, M.; Martin, S. J. Granzymes in cancer and immunity. Cell Death Differ. 2010, 17, 616-623.
27. Pham, C. T.; Ley, T. J. Dipeptidyl peptidase I is required for the processing and activation of granzymes A and B in vivo. Proc. Natl. Acad. Sci. USA 1999, 96, 8627-8632.
28. Chowdhury, D.; Lieberman, J. Death by a thousand cuts: Granzyme pathways of programmed cell death. Annu. Rev. Immunol. 2008, 26, 389-420.
29. Bromley, S. K.; Burack, W. R.; Johnson, K. G.; Somersalo, K.; Sims, T. N.; Sumen, C.; Davis, M. M.; Shaw, A. S.; Allen, P. M.; Dustin, M. L. The immunological synapse. Annu. Rev. Immunol. 2001, 19, 375-396.
30. Huse, M.; Quann, E. J.; Davis, M. M. Shouts, whispers and the kiss of death: Directional secretion in T cells. Nat. Immunol. 2008, 9, 1105-1111.
31. Afonina, I. S.; Cullen, S. P.; Martin, S. J. Cytotoxic and non-cytotoxic roles of the CTL/NK protease granzyme B. Immunol. Rev. 2010, 235, 105-116.
32. Baran, K.; Dunstone, M.; Chia, J.; Ciccone, A.; Browne, K. A.; Clarke, C. J.; Lukoyanova, N.; Saibil, H.; Whisstock, J. C.; Voskoboinik, I.; et al. The molecular basis for perforin oligomerization and transmembrane pore assembly. Immunity 2009, 30, 684-695.
33. Law, R. H.; Lukoyanova, N.; Voskoboinik, I.; Caradoc-Davies, T. T.; Baran, K.; Dunstone, M. A.; D'Angelo, M. E.; Orlova, E. V.; Coulibaly, F.; Verschoor, S.; et al. The structural basis for membrane binding and pore formation by lymphocyte perforin. Nature 2010, 468, 447-451.
34. Thiery, J.; Keefe, D.; Saffarian, S.; Martinvalet, D.; Walch, M.; Boucrot, E.; Kirchhausen, T.; Lieberman, J. Perforin activates clathrin-and dynamin-dependent endocytosis, which is required for plasma membrane repair and delivery of granzyme B for granzyme-mediated apoptosis. Blood 2010, 115, 1582-1593.
35. Thiery, J.; Keefe, D.; Boulant, S.; Boucrot, E.; Walch, M.; Martinvalet, D.; Goping, I. S.; Bleackley, R. C.; Kirchhausen, T.; Lieberman, J. Perforin pores in the endosomal membrane trigger the release of endocytosed granzyme B into the cytosol of target cells. Nat. Immunol. 2011, 12, 770-777.
36. Gross, C.; Koelch, W.; DeMaio, A.; Arispe, N.; Multhoff, G. Cell surface-bound heat shock protein 70 (Hsp70) mediates perforin-independent apoptosis by specific binding and uptake of granzyme B. J. Biol. Chem. 2003, 278, 41173-41181.
37. Gehrmann, M.; Stangl, S.; Kirschner, A.; Foulds, G. A.; Sievert, W.; Doss, B. T.; Walch, A.; Pockley, A. G.; Multhoff, G. Immunotherapeutic targeting of membrane Hsp70-expressing tumors using recombinant human granzyme B. PLoS One 2012, 7, e41341.
38. Jabulowsky, R. A.; Oberoi, P.; Bähr-Mahmud, H.; Dälken, B.; Wels, W. S. Surface chargemodification prevents sequestration and enhances tumor-cell specificity of a recombinant granzyme B-TGFalpha fusion protein. Bioconjug. Chem. 2012, 23, 1567-1576.
39. Boivin, W. A.; Cooper, D. M.; Hiebert, P. R.; Granville, D. J. Intracellular versus extracellular granzyme B in immunity and disease: challenging the dogma. Lab. Invest. 2009, 89, 1195-1220.
40. Thornberry, N. A.; Rano, T. A.; Peterson, E. P.; Rasper, D. M.; Timkey, T.; Garcia-Calvo, M.; Houtzager, V. M.; Nordstrom, P. A.; Roy, S.; Vaillancourt, J. P.; et al. A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. J. Biol. Chem. 1997, 272, 17907-17911.
41. Adrain, C.; Murphy, B. M.; Martin, S. J. Molecular ordering of the caspase activation cascade initiated by the cytotoxic T lymphocyte/natural killer (CTL/NK) protease granzyme B. J. Biol. Chem. 2005, 280, 4663-4673.
42. Barry, M.; Heibein, J. A.; Pinkoski, M. J.; Lee, S. F.; Moyer, R. W.; Green, D. R.; Bleackley, R. C. Granzyme B short-circuits the need for caspase 8 activity during granule-mediated cytotoxic T-lymphocyte killing by directly cleaving Bid. Mol. Cell. Biol. 2000, 20, 3781-3794.
43. Waterhouse, N. J.; Sedelies, K. A.; Browne, K. A.; Wowk, M. E.; Newbold, A.; Sutton, V. R.; Clarke, C. J.; Oliaro, J.; Lindemann, R. K.; Bird, P. I.; et al. A central role for Bid in granzyme Binduced apoptosis. J. Biol. Chem. 2005, 280, 4476-4482.
44. Thomas, D. A.; Du, C.; Xu, M.; Wang, X.; Ley, T. J. DFF45/ICAD can be directly processed by granzyme B during the induction of apoptosis. Immunity 2000, 12, 621-632.
45. Sharif-Askari, E.; Alam, A.; Rheaume, E.; Beresford, P. J.; Scotto, C.; Sharma, K.; Lee, D.; DeWolf, W. E.; Nuttall, M. E.; Lieberman, J.; et al. Direct cleavage of the human DNA fragmentation factor-45 by granzyme B induces caspase-activated DNase release and DNA fragmentation. EMBO J. 2001, 20, 3101-3113.
46. Adrain, C.; Duriez, P. J.; Brumatti, G.; Delivani, P.; Martin, S. J. The cytotoxic lymphocyte protease, granzyme B, targets the cytoskeleton and perturbs microtubule polymerization dynamics. J. Biol. Chem. 2006, 281, 8118-8125.
47. Zhang, D.; Beresford, P. J.; Greenberg, A. H.; Lieberman, J. Granzymes A and B directly cleave lamins and disrupt the nuclear lamina during granule-mediated cytolysis. Proc. Natl. Acad. Sci. USA 2001, 98, 5746-5751.
48. Froelich, C. J.; Hanna, W. L.; Poirier, G. G.; Duriez, P. J.; D'Amours, D.; Salvesen, G. S.; Alnemri, E. S.; Earnshaw, W. C.; Shah, G. M. Granzyme B/perforin-mediated apoptosis of Jurkat cells results in cleavage of poly(ADP-ribose) polymerase to the 89-kDa apoptotic fragment and less abundant 64-kDa fragment. Biochem. Biophys. Res. Commun. 1996, 227, 658-665.
49. Giesübel, U.; Dälken, B.; Mahmud, H.; Wels, W. S. Cell binding, internalization and cytotoxic activity of human granzyme B expressed in the yeast Pichia pastoris. Biochem. J. 2006, 394, 563-573.
50. Liu, Y.; Cheung, L. H.; Hittelman, W. N.; Rosenblum, M. G. Targeted delivery of human pro-apoptotic enzymes to tumor cells: In vitro studies describing a novel class of recombinant highly cytotoxic agents. Mol. Cancer Ther. 2003, 2, 1341-1350.
51. Kurschus, F. C.; Kleinschmidt, M.; Fellows, E.; Dornmair, K.; Rudolph, R.; Lilie, H.; Jenne, D. E. Killing of target cells by redirected granzyme B in the absence of perforin. FEBS Lett. 2004, 562, 87-92.
52. Lorentsen, R. H.; Fynbo, C. H.; Thogersen, H. C.; Etzerodt, M.; Holtet, T. L. Expression, refolding, and purification of recombinant human granzyme B. Protein Expr. Purif. 2005, 39, 18-26.
53. Stahnke, B.; Thepen, T.; Stocker, M.; Rosinke, R.; Jost, E.; Fischer, R.; Tur, M. K.; Barth, S. Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes. Mol. Cancer Ther. 2008, 7, 2924-2932.
54. Gehrmann, M.; Doss, B. T.; Wagner, M.; Zettlitz, K. A.; Kontermann, R. E.; Foulds, G.; Pockley, A. G.; Multhoff, G. A novel expression and purification system for the production of enzymatic and biologically active human granzyme B. J. Immunol. Methods 2011, 371, 8-17.
55. Cereghino, J. L.; Cregg, J. M. Heterologous protein expression in the methylotrophic yeast Pichia pastoris. FEMS Microbiol. Rev. 2000, 24, 45-66.
56. Pham, C. T.; Thomas, D. A.; Mercer, J. D.; Ley, T. J. Production of fully active recombinant murine granzyme B in yeast. J. Biol. Chem. 1998, 273, 1629-1633.
57. Sun, J.; Bird, C. H.; Buzza, M. S.; McKee, K. E.; Whisstock, J. C.; Bird, P. I. Expression and purification of recombinant human granzyme B from Pichia pastoris. Biochem. Biophys. Res. Commun. 1999, 261, 251-255.
58. Dälken, B.; Jabulowsky, R. A.; Oberoi, P.; Benhar, I.; Wels, W. S. Maltose-binding protein enhances secretion of recombinant human granzyme B accompanied by in vivo processing of a precursor MBP fusion protein. PLoS One 2010, 5, e14404.
59. Liu, Y.; Zhang, W.; Niu, T.; Cheung, L. H.; Munshi, A.; Meyn, R. E.; Rosenblum, M. G. Targeted apoptosis activation with GrB/scFvMEL modulates melanoma growth, metastatic spread, chemosensitivity, and radiosensitivity. Neoplasia 2006, 8, 125-135.
60. Wels, W.; Harwerth, I. M.; Mueller, M.; Groner, B.; Hynes, N. E. Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor. Cancer Res. 1992, 52, 6310-6317.
61. Wels, W.; Beerli, R.; Hellmann, P.; Schmidt, M.; Marte, B. M.; Kornilova, E. S.; Hekele, A.; Mendelsohn, J.; Groner, B.; Hynes, N. E. EGF receptor and p185erbB-2-specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins. Int. J. Cancer 1995, 60, 137-144.
62. Schmidt, M.; Wels, W. Targeted inhibition of tumour cell growth by a bispecific single-chain toxin containing an antibody domain and TGF alpha. Br. J. Cancer 1996, 74, 853-862.
63. Zenke, M.; Steinlein, P.; Wagner, E.; Cotten, M.; Beug, H.; Birnstiel, M. L. Receptor-mediated endocytosis of transferrin-polycation conjugates: an efficient way to introduce DNA into hematopoietic cells. Proc. Natl. Acad. Sci. USA 1990, 87, 3655-3659.
64. Maurer-Gebhard, M.; Schmidt, M.; Azemar, M.; Altenschmidt, U.; Stöcklin, E.; Wels, W.; Groner, B. Systemic treatment with a recombinant erbB-2 receptor-specific tumor toxin efficiently reduces pulmonary metastases in mice injected with genetically modified carcinoma cells. Cancer Res. 1998, 58, 2661-2666.
65. Kanatani, I.; Lin, X.; Yuan, X.; Manorek, G.; Shang, X.; Cheung, L. H.; Rosenblum, M. G.; Howell, S. B. Targeting granzyme B to tumor cells using a yoked human chorionic gonadotropin. Cancer Chemother. Pharmacol. 2011, 68, 979-990.
66. Bird, C. H.; Sun, J.; Ung, K.; Karambalis, D.; Whisstock, J. C.; Trapani, J. A.; Bird, P. I. Cationic sites on granzyme B contribute to cytotoxicity by promoting its uptake into target cells. Mol. Cell. Biol. 2005, 25, 7854-7867.
67. Shi, L.; Keefe, D.; Durand, E.; Feng, H.; Zhang, D.; Lieberman, J. Granzyme B binds to target cells mostly by charge and must be added at the same time as perforin to trigger apoptosis. J. Immunol. 2005, 174, 5456-5461.
68. Kurschus, F. C.; Fellows, E.; Stegmann, E.; Jenne, D. E. Granzyme B delivery via perforin is restricted by size, but not by heparan sulfate-dependent endocytosis. Proc. Natl. Acad. Sci. USA 2008, 105, 13799-13804.
69. Metkar, S. S.; Wang, B.; Aguilar-Santelises, M.; Raja, S. M.; Uhlin-Hansen, L.; Podack, E.; Trapani, J. A.; Froelich, C. J. Cytotoxic cell granule-mediated apoptosis: Perforin delivers granzyme B-serglycin complexes into target cells without plasma membrane pore formation. Immunity 2002, 16, 417-428.
70. Raja, S. M.; Metkar, S. S.; Honing, S.; Wang, B.; Russin, W. A.; Pipalia, N. H.; Menaa, C.; Belting, M.; Cao, X.; Dressel, R.; et al. A novel mechanism for protein delivery: Granzyme B undergoes electrostatic exchange from serglycin to target cells. J. Biol. Chem. 2005, 280, 20752-20761.
71. Kurschus, F. C.; Bruno, R.; Fellows, E.; Falk, C. S.; Jenne, D. E. Membrane receptors are not required to deliver granzyme B during killer cell attack. Blood 2005, 105, 2049-2058.
72. Estebanez-Perpina, E.; Fuentes-Prior, P.; Belorgey, D.; Braun, M.; Kiefersauer, R.; Maskos, K.; Huber, R.; Rubin, H.; Bode, W. Crystal structure of the caspase activator human granzyme B, a proteinase highly specific for an Asp-P1 residue. Biol. Chem. 2000, 381, 1203-1214.
73. Buzza, M. S.; Zamurs, L.; Sun, J.; Bird, C. H.; Smith, A. I.; Trapani, J. A.; Froelich, C. J.; Nice, E. C.; Bird, P. I. Extracellular matrix remodeling by human granzyme B via cleavage of vitronectin, fibronectin, and laminin. J. Biol. Chem. 2005, 280, 23549-23558.
74. Tak, P. P.; Spaeny-Dekking, L.; Kraan, M. C.; Breedveld, F. C.; Froelich, C. J.; Hack, C. E. The levels of soluble granzyme A and B are elevated in plasma and synovial fluid of patients with rheumatoid arthritis (RA). Clin. Exp. Immunol. 1999, 116, 366-370.
75. Ronday, H. K.; van der Laan, W. H.; Tak, P. P.; de Roos, J. A.; Bank, R. A.; TeKoppele, J. M.; Froelich, C. J.; Hack, C. E.; Hogendoorn, P. C.; Breedveld, F. C.; et al. Human granzyme B mediates cartilage proteoglycan degradation and is expressed at the invasive front of the synovium in rheumatoid arthritis. Rheumatology (Oxford) 2001, 40, 55-61.
76. Skjelland, M.; Michelsen, A. E.; Krohg-Sorensen, K.; Tennoe, B.; Dahl, A.; Bakke, S.; Brosstad, F.; Damas, J. K.; Russell, D.; Halvorsen, B.; et al. Plasma levels of granzyme B are increased in patients with lipid-rich carotid plaques as determined by echogenicity. Atherosclerosis 2007, 195, e142-146.
77. Saito, Y.; Kondo, H.; Hojo, Y. Granzyme B as a novel factor involved in cardiovascular diseases. J. Cardiol. 2011, 57, 141-147.
78. Boivin, W. A.; Shackleford, M.; Vanden Hoek, A.; Zhao, H.; Hackett, T. L.; Knight, D. A.; Granville, D. J. Granzyme B cleaves decorin, biglycan and soluble betaglycan, releasing active transforming growth factor-beta1. PLoS One 2012, 7, e33163.
79. Wang, T.; Lee, M. H.; Choi, E.; Pardo-Villamizar, C. A.; Lee, S. B.; Yang, I. H.; Calabresi, P. A.; Nath, A. Granzyme B-induced neurotoxicity is mediated via activation of PAR-1 receptor and Kv1. 3 channel. PLoS One 2012, 7, e43950.
80. Buzza, M. S.; Bird, P. I. Extracellular granzymes: Current perspectives. Biol. Chem. 2006, 387, 827-837.
81. Sun, J.; Bird, C. H.; Sutton, V.; McDonald, L.; Coughlin, P. B.; De Jong, T. A.; Trapani, J. A.; Bird, P. I. A cytosolic granzyme B inhibitor related to the viral apoptotic regulator cytokine response modifier A is present in cytotoxic lymphocytes. J. Biol. Chem. 1996, 271, 27802-27809.
82. Bird, C. H.; Sutton, V. R.; Sun, J.; Hirst, C. E.; Novak, A.; Kumar, S.; Trapani, J. A.; Bird, P. I. Selective regulation of apoptosis: The cytotoxic lymphocyte serpin proteinase inhibitor 9 protects against granzyme B-mediated apoptosis without perturbing the Fas cell death pathway. Mol. Cell. Biol. 1998, 18, 6387-6398.
83. Classen, C. F.; Bird, P. I.; Debatin, K. M. Modulation of the granzyme B inhibitor proteinase inhibitor 9 (PI-9) by activation of lymphocytes and monocytes in vitro and by Epstein-Barr virus and bacterial infection. Clin. Exp. Immunol. 2006, 143, 534-542.
84. Hirst, C. E.; Buzza, M. S.; Bird, C. H.; Warren, H. S.; Cameron, P. U.; Zhang, M.; Ashton-Rickardt, P. G.; Bird, P. I. The intracellular granzyme B inhibitor, proteinase inhibitor 9, is up-regulated during accessory cell maturation and effector cell degranulation, and its overexpression enhances CTL potency. J. Immunol. 2003, 170, 805-815.
85. Bots, M.; de Bruin, E.; Rademaker-Koot, M. T.; Medema, J. P. Proteinase inhibitor-9 expression is induced by maturation in dendritic cells via p38 MAP kinase. Hum. Immunol. 2007, 68, 959-964.
86. Medema, J. P.; de Jong, J.; Peltenburg, L. T.; Verdegaal, E. M.; Gorter, A.; Bres, S. A.; Franken, K. L.; Hahne, M.; Albar, J. P.; Melief, C. J.; et al. Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc. Natl. Acad. Sci. USA 2001, 98, 11515-11520.
87. Rousalova, I.; Krepela, E.; Prochazka, J.; Cermak, J.; Benkova, K. Expression of proteinase inhibitor-9/serpinB9 in non-small cell lung carcinoma cells and tissues. Int. J. Oncol. 2010, 36, 275-283.
88. ten Berge, R. L.; Meijer, C. J.; Dukers, D. F.; Kummer, J. A.; Bladergroen, B. A.; Vos, W.; Hack, C. E.; Ossenkoppele, G. J.; Oudejans, J. J. Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma. Blood 2002, 99, 4540-4546.
89. van Houdt, I. S.; Oudejans, J. J.; van den Eertwegh, A. J.; Baars, A.; Vos, W.; Bladergroen, B. A.; Rimoldi, D.; Muris, J. J.; Hooijberg, E.; Gundy, C. M.; et al. Expression of the apoptosis inhibitor protease inhibitor 9 predicts clinical outcome in vaccinated patients with stage III and IV melanoma. Clin. Cancer Res. 2005, 11, 6400-6407.
90. Soriano, C.; Mukaro, V.; Hodge, G.; Ahern, J.; Holmes, M.; Jersmann, H.; Moffat, D.; Meredith, D.; Jurisevic, C.; Reynolds, P. N.; et al. Increased proteinase inhibitor-9 (PI-9) and reduced granzyme B in lung cancer: mechanism for immune evasion? Lung Cancer 2012, 77, 38-45.
91. Losasso, V.; Schiffer, S.; Barth, S.; Carloni, P. Design of human granzyme B variants resistant to serpin B9. Proteins 2012, 80, 2514-2522.
92. Sutton, V. R.; Sedelies, K.; Dewson, G.; Christensen, M. E.; Bird, P. I.; Johnstone, R. W.; Kluck, R. M.; Trapani, J. A.; Waterhouse, N. J. Granzyme B triggers a prolonged pressure to die in Bcl-2 overexpressing cells, defining a window of opportunity for effective treatment with ABT-737. Cell Death Dis. 2012, 3, e344.
93. Zhang, X.; Sawyer, G. J.; Dong, X.; Qiu, Y.; Collins, L.; Fabre, J. W. The in vivo use of chloroquine to promote non-viral gene delivery to the liver via the portal vein and bile duct. J. Gene Med. 2003, 5, 209-218.
94. Raynes, K. Bisquinoline antimalarials: their role in malaria chemotherapy. Int. J. Parasitol. 1999, 29, 367-379.
95. Zhao, J.; Zhang, L. H.; Jia, L. T.; Zhang, L.; Xu, Y. M.; Wang, Z.; Yu, C. J.; Peng, W. D.; Wen, W. H.; Wang, C. J.; et al. Secreted antibody/granzyme B fusion protein stimulates selective killing of HER2-overexpressing tumor cells. J. Biol. Chem. 2004, 279, 21343-21348.
96. Fominaya, J.; Wels, W. Target cell-specific DNA transfer mediated by a chimeric multidomain protein. Novel non-viral gene delivery system. J. Biol. Chem. 1996, 271, 10560-10568.
97. Uherek, C.; Fominaya, J.; Wels, W. A modular DNA carrier protein based on the structure of diphtheria toxin mediates target cell-specific gene delivery. J. Biol. Chem. 1998, 273, 8835-8841.
98. Antignani, A.; Youle, R. J. How do Bax and Bak lead to permeabilization of the outer mitochondrial membrane? Curr. Opin. Cell Biol. 2006, 18, 685-689.
99. Sampieri, K.; Fodde, R. Cancer stem cells and metastasis. Semin. Cancer Biol. 2012, 22, 187-193.
100. Robertson, M. J.; Cochran, K. J.; Cameron, C.; Le, J. M.; Tantravahi, R.; Ritz, J. Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Exp. Hematol. 1996, 24, 406-415.
101. Oberoi, P.; Jabulowsky, R. A.; Bähr-Mahmud, H.; Wels, W. S. Georg-Speyer-Haus, Frankfurt, Germany. 2013, unpublished work.
102. Müller, T.; Uherek, C.; Maki, G.; Chow, K. U.; Schimpf, A.; Klingemann, H. G.; Tonn, T.; Wels, W. S. Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells. Cancer Immunol. Immunother. 2008, 57, 411-423.